Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

Research study indicates the worldwide TB testing market tops $8 billion

Kalorama Information : 14 June, 2007  (New Product)
A new study from Kalorama Information entitled 'Global Tuberculosis Strategies' reckons the total theoretical market potential worldwide for TB testing products and therapeutics now tops $8 billion.
The market potential is based on currently reported TB status and pricing structures.

Even though TB was nearly extinct in the latter part of the last century, tuberculosis is now presenting a major public health crisis as more than 1.6 billion people are infected and global hotspots continue to be burdened with insufficient screening, diagnosis, and treatment.

Lack of proper diagnosis is a major barrier to tuberculosis treatment, and the report details current screening techniques and the potential market for advanced diagnostic products.

Skin testing remains the most common form of testing and though the Mantoux test dominates, others are being developed that will impact the market.

Sputum smears and cultures, considered better options for diagnosis, lag behind skin testing as they pose difficulties in field use.

The report illustrates three primary focal points for the development of a global strategy for combating tuberculosis - potential market, epidemiology (tuberculosis patient trends) and technology - and reviews how diagnostic and pharmaceutical companies can incorporate these focal points into their own TB eradication plan.

'With tuberculosis you've got to cure the individual and minimise the transmission to other persons, which can only be done through advanced screenings and treatments being made available to hard hit regions', notes Kenneth G Krul, PhD, the report's author.

'Because of the contagiousness of this frightening disease, there are huge payoffs for investment in diagnostics and therapeutics, which have not yet been tapped'.

The study contains an extensive tuberculosis etiology, epidemiologic statistics, including 30 tables of incidence, prevalence, and mortality statistics by country, region, and type of tuberculosis, and a comprehensive glossary of terms.

The 'Global Tuberculosis Strategies' study also includes theoretical market sizes for screening/diagnosis as well as treatment by region and by type of TB (MDR and non-MDR) and a comprehensive review of products for the treatment of TB.

Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo